ADAMO, Vincenzo
 Distribuzione geografica
Continente #
NA - Nord America 6.582
EU - Europa 6.342
AS - Asia 1.102
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 6
SA - Sud America 5
AF - Africa 2
Totale 14.049
Nazione #
US - Stati Uniti d'America 6.563
IE - Irlanda 1.906
SE - Svezia 1.582
CN - Cina 955
IT - Italia 614
UA - Ucraina 483
PL - Polonia 467
DE - Germania 342
FI - Finlandia 251
GB - Regno Unito 205
FR - Francia 171
BE - Belgio 154
AT - Austria 95
IN - India 68
VN - Vietnam 50
RU - Federazione Russa 22
CA - Canada 18
CZ - Repubblica Ceca 12
EU - Europa 8
IR - Iran 8
JP - Giappone 8
ES - Italia 6
AU - Australia 5
HR - Croazia 5
CH - Svizzera 4
HK - Hong Kong 4
NL - Olanda 4
LV - Lettonia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BG - Bulgaria 2
CL - Cile 2
IL - Israele 2
LU - Lussemburgo 2
MK - Macedonia 2
RO - Romania 2
TH - Thailandia 2
ZA - Sudafrica 2
AL - Albania 1
AR - Argentina 1
BR - Brasile 1
CO - Colombia 1
DK - Danimarca 1
EE - Estonia 1
GR - Grecia 1
HU - Ungheria 1
ID - Indonesia 1
IQ - Iraq 1
LT - Lituania 1
MM - Myanmar 1
MX - Messico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
RS - Serbia 1
SA - Arabia Saudita 1
TR - Turchia 1
Totale 14.049
Città #
Dublin 1.904
Chandler 1.368
Jacksonville 1.009
Nyköping 843
Warsaw 464
Beijing 410
Ashburn 345
New York 281
Ann Arbor 277
Princeton 271
Medford 258
Dearborn 250
Cambridge 240
Des Moines 208
Brussels 153
Boardman 152
Messina 131
Woodbridge 84
Jinan 83
Vienna 79
Lancaster 70
Wilmington 59
Pune 56
Shenyang 54
San Mateo 53
Dong Ket 46
Nanjing 42
Tianjin 37
Hebei 34
Zhengzhou 33
Houston 27
Haikou 25
Hangzhou 23
Seattle 23
Nanchang 21
Changsha 19
Leawood 19
Ningbo 19
Jiaxing 18
Taizhou 18
Guangzhou 17
Taiyuan 15
Grammichele 14
Washington 14
Fort Washington 13
Fuzhou 13
Helsinki 13
Lanzhou 13
Milan 13
Norwalk 13
Bremen 11
Brno 11
Augusta 10
Rome 10
Monmouth Junction 9
Clearwater 8
Falls Church 8
Modica 8
Edinburgh 6
Saint Petersburg 6
Tappahannock 6
Ardabil 5
Catania 5
Kunming 5
London 5
Montréal 5
Ottawa 5
Shenzhen 5
Toronto 5
Auburn Hills 4
Brescia 4
Colombes 4
Hong Kong 4
Kemerovo 4
La Spezia 4
Lappeenranta 4
Las Vegas 4
Mumbai 4
Napoli 4
Redwood City 4
Tokyo 4
Brockport 3
Hanoi 3
Hefei 3
Los Angeles 3
Madrid 3
Mountain View 3
Novi 3
Novokuznetsk 3
Radomsko 3
Redmond 3
Reggio Calabria 3
San Giovanni Rotondo 3
Sassari 3
Savona 3
Trepuzzi 3
Turin 3
Wuhan 3
Albano Laziale 2
Ameno 2
Totale 9.880
Nome #
PARAGANGLIOMA MALIGNO DEL CORPO CAROTIDEO.Rilievi Clinici, Morfologici, Istochimici E Ultrastrutturali Su Un Caso. 364
Su di un caso di pseudomyxoma peritonei con diffusione spontanea alla pleura. 127
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 120
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 103
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer 92
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 89
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 89
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 89
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 88
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 88
NSCLC and HER2: between lights and shadows 88
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 87
Intralesional sonographically guided injections of lymphokine- activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: A pilot study 86
Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen 85
Epirubucin (EPI) and Paclitaxel (TAX) in advanced breast cancer.a phase II studyi 85
Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methlylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients’ outcome and correlation with p53 codon 72 mutations. 85
Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. 84
Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study 83
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 83
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 83
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 82
SPONTANEOUS TRANSFORMATION AND IMMORTALIZATION OF PERITONEAL- MACROPHAGES OF HUMAN-ORIGIN 81
Hereditary breast/ovarian cancer families: The impact of mutation prediction models on BRCA1/2 mutation screening costs. 80
The Mam-1 GOCSI Trial: a Randomised Trial with Factorial Design of Chemo-Endocrine Adjuvant Treatment in Node-Positive (N+) Early Breast Cancer (EBC). 80
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer 79
HER-2 overexpression in advanced node-positive gastric carcinomas: is there any relationship with other clinico-pathological histoprognostic parameters? 79
[Serum levels of copper and zinc in patients with lung cancer] 77
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 77
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation 77
Immunoexpression of lactoferrin in triple-negative breast cancer patients: A proposal to select a less aggressive subgroup 76
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review 75
Antiblastic treatment of advanced cervical carcinoma and its recurrences: assessment of four different polychemotherapies used for a decade. 74
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 74
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site 74
A study of endometrial adenocarcinoma treated with tamoxifen by scanning and transmission electron microscopy. 72
The treatment of peritoneal carcinomatosis in elderly patients. 72
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study. 72
Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. 71
Gefitinib in lung cancer therapy. Clinical results, predictive markers of response and future perspectives. 71
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 71
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 71
Detection Of Lynphocytic β - Endorphin In Cancer Patients During Hospedalization And After In Vitro Culture With IL 2. 71
Safety of Capecitabine plus Bevacizumab in heavily treated patients with metastatic colorectal cancer (MCRC) 70
Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. 70
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. 70
Trattamento palliativo dei tumori del retto-sigma mediante elettrocoagulazione endoscopica.” 69
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 69
I Tumori del coloretto. La chemioterapia della fase avanzata. 68
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 68
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 68
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 68
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 67
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 67
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 67
Maintenance Therapy with Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 67
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. 66
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 66
An immunohistochemical investigation of pre-metastatic niche (PMN) in node-negative invasive breast carcinomas 66
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. 65
Phase II study paclitaxel (PTX) and cisplatin (Cis) in advanced and recurrent head&neck cancer 65
Combination of Gemcitabine (GEM and Liposomal Pegylate Doxorubicin (PLD) in recurrent/ metastatic breast carcinoma: a phase II study. 65
May the istotype influence the response to pemetrexed in patients with non small cell lung cancer? Preliminary data of our clinical experience. 65
Gefitinib versus Erlotinib treatment in Non Small Cell Lung Cancer (NSCLC): comparison of two clinical experiences. 65
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 65
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study 64
Gemcitabine (GEM) and cisplatin (Cis) in advanced/metastatic transitional cell carcinoma (TCC) of bladder: Phase II study 64
Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck 64
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 64
Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study. 64
CyberKnife Radiosurgery Alone or Combined with "Dose Dense" Temozolomide Administration for Recurrent Gliomas. 63
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 63
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 63
ACTIVITY AND TOXICITY OF GEMCITABINE AND GEMCITABINE + VINORELBINE IN ADVANCED NSCLC EDERLY PATIENTS .PHASE II DATA FROM THE MULTICENTER ITALIAN LUNG CANCER IN THE ELDERLY STUDY(MILES) RANDOMIZED TRIAL 62
Treatment of advanced and/or metastatic epidermoid carcinoma of the head and neck: an effective combination chemotherapy with bleomycin, methotrexate and ftorafur. 62
SAFETY AND ACTIVITY OF ERLOTINIB (TARCEVA) IN HEAVILY PRE-TREATED PATIENTS WITH METASTATIC, REFRACTORY NON SMALL CELL LUNG CANCER 62
FCM detection of lymphocytic beta-endorphin in cancer patients during hospitalization and after in vitro culture with IL2 62
TCC superficiale della vescica: identificazione nel sedimento urinario di mediatori di proliferazione cellulare quali possibili indici di recidiva e progressione neoplastica. 62
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: 62
gemcitabine and pegylated liposomial doxorubicin in recurrent epithelial ovarian cancer (REOC).Preliminary report a phase II study 62
AIOM Conference 2004. Docetaxel: a recent conquest in the adjuvant therapy of breast cancer 61
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) 61
The treatment of recurrent and metastatic cervical carcinoma. Evaluation of an antiblastic combination of methotrexate-adriamycin-bleomycin (MAB) 61
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 61
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 61
A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin 60
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 60
Breast. La terapia primaria: stato dell'arte 60
Activity and tolerability of cisplatin (CDDP) and fotemustine (FTM) in non-small cell lung cancer (NSCLC) patients (PTS) with brain metastases (BM): A multicentric phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). 60
Il ruolo dell'ormonoterapia nel carcinoma della mammella in eta' geriatrica 60
Metastasis risk assessment in breast cancer (BC): a preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes 60
Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives. 60
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 60
Phase II trial ZD1839(IRESSA)second-third line in patients with advanced/metastatic non small cell lung cancer (NSCLC):preliminary results 59
Peritoneal carcinomatosis of colorectal origin. 59
Phase III trial comparing 3-6months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: Safety and compliance in the TOSCA trial 59
Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. 58
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile. 58
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile 57
Incidence and preferential localizations of bone metastases: biomolecolar and clinical implications. 57
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 57
Totale 7.422
Categoria #
all - tutte 42.418
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.418


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201997 0 0 0 0 0 0 0 0 14 19 6 58
2019/20202.020 300 118 28 101 23 262 250 239 49 257 330 63
2020/20212.239 224 48 416 221 205 223 115 159 65 238 193 132
2021/20221.767 19 244 30 45 58 16 104 64 15 318 264 590
2022/20235.363 388 490 215 417 381 512 88 349 2.263 35 165 60
2023/20241.248 118 199 83 124 103 495 66 56 4 0 0 0
Totale 14.320